Press Releases

InterSystems, a creative data technology provider managing over one billion healthcare records globally, and MyCLNQ Health, a digital health solutions leader, have announced a regional strategic partnership to help hospitals enhance patient engagement and increase service offerings across Asia. As part of the collaboration MyCLNQ will embed the InterSystems IRIS for Health™ data platform into its customizable, white-label mobile technologies to provide interoperability between MyCLNQ an

Waters Corporation and BD today announced a definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters, creating an innovative life science and diagnostics leader with pioneering technologies and an industry-leading financial outlook. The agreement is structured as a tax-efficient Reverse Morris Trust transaction valued at approximately $17.5 billion. Compelling Strategic and Financial Benefits The compan

IntelePeer, the leading end-to-end Conversational AI platform, today announced a strategic partnership with SOAP Health, the pioneer of AI-First Primary Care™, to transform both administrative and clinical efficiency across the healthcare industry. The collaboration combines IntelePeer’s SmartAgent™ and SmartAnalytics™ solutions with SOAP Health’s patented, animated, voice-based digital human ClinicalAI™ assistant to deliver a fully automated, smart patient

FUJIFILM Healthcare Americas Corporation, a leading provider of medical imaging and informatics solutions, today announced the launch of several advanced automated functions for its FDR Visionary Suite digital radiography room. Optimized to support high-volume imaging in hospital radiology departments and imaging centers, the automation features are designed to enhance workflow and improve the patient and technologist experience for a wide range of general radiology exams. The advan

Quest Diagnostics, a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test from Fujirebio, a global leader in the field of high-quality IVD testing. Quest plans to make the test available to physicians and biopharmaceutical collaborators later this summer. The test is the first blood-based IV

Exact Sciences Corp. a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare coverage through the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program (MolDX) for serial use in patients with stage II, III and resectable stage IV colorectal cancer (CRC) in the adjuvant and recurrence monitoring settings over a five-year period. The final LC

Masimo a global medical technology company that develops and manufactures innovative noninvasive monitoring solutions, has joined the American Heart Association Center for Health Technology & Innovation’s (the Center) Innovators’ Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. The Innovators’ Network is a health care technology consortium that connects entrepreneurs, provider

 Xtant Medical Holdings, Inc. a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that the company has entered into agreements to sell certain Coflex® and CoFix® interlaminar stabilization implant assets and all OUS entities of Paradigm Spine GmbH, to Companion Spine, LLC, a French-American company fully dedicated to posterior dynamic spine stabilization and motion preservation sy

Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) labeling for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The updated labeling now includes approval for the system in the treatment of drug refractory, symptomatic persistent atrial fibrillation (AF), an arrythmia in which the heart beats abnormally for at least seven days. AF affects an estimated 59 million people worldwide and many

Medtronic, a global leader in healthcare technology, today announced that it has treated the first patient in its SPYRAL GEMINI Pilot program (including 'OFF MED’ and 'ON MED’ studies).* The first patient was treated by Dr. Barry Bertolet at Cardiology Associates of North Mississippi and North Mississippi Medical Center in Tupelo. With this trial, Medtronic intends to investigate the feasibility of combined denervation of both the renal and common hepatic (liver) arteries